STOCK TITAN

AIM ImmunoTech sets Dec. 8 for adjourned annual meeting

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

AIM ImmunoTech adjourned its 2026 annual meeting on November 17 after a quorum was not present; no business was conducted. Proxies represented approximately 32.5% of shares entitled to vote, below the 33 and 1/3% quorum threshold. The adjournment also gives stockholders additional time to review the proxy materials and vote.

The virtual meeting is scheduled to reconvene on December 8, 2026, at 11:00 a.m. Eastern Time. The September 28, 2026 record date and proposals remain unchanged. Stockholders who already voted and do not want to change their vote do not need to take any action.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Quorum threshold 33 and 1/3% Required percentage of common stock outstanding and entitled to vote to be present or represented by proxy.
Proxy representation Approximately 32.5% Shares entitled to vote represented by submitted proxies when the annual meeting was adjourned.
Reconvened annual meeting December 8, 2026, at 11:00 a.m. Eastern Time Meeting will continue in a virtual format.
Record date September 28, 2026 Date remains in effect for determining stockholders entitled to vote at the adjourned meeting.
quorum regulatory
"to constitute a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
record date regulatory
"The record date for the determination of stockholders"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000946644 0000946644 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 17, 2026

 

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-27072   52-0845822

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2117 SW Highway 484, Ocala, Florida   34473
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (352) 448-7797

 

Not Applicable

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   AIM   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On November 18, 2026, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing that it had adjourned its 2026 Annual Meeting of Stockholders. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01 Other Events.

 

On November 17, 2026, the Company convened and then determined to adjourn, without conducting any business, its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) because the Company did not have a sufficient number of shares of the Company’s common stock present or represented by proxy at the Annual Meeting to constitute a quorum and to provide stockholders additional time to review the proxy materials and submit proxies to vote at the Annual Meeting. As was announced at the Annual Meeting, such meeting will reconvene at 11:00 A.M. Eastern Time on December 8, 2026, virtually at https://web.viewproxy.com/AIM/2026.

 

The record date for the determination of stockholders of the Company entitled to vote at the adjourned Annual Meeting remains the close of business on September 28, 2026. No changes have been made to the proposals to be voted on by the stockholders at the Annual Meeting. Stockholders who have previously submitted their proxy or otherwise voted and do not want to change their vote do not need to take any action.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated November 18, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 18, 2026 AIM ImmunoTech Inc.
     
  By: /s/ Thomas K. Equels
    Thomas K. Equels
    Chief Executive Officer

 

 

 

Exhibit 99.1

 

 

AIM ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

 

OCALA, Fla., November 18, 2026 / AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for and convened on November 17, 2026, has been adjourned until December 8, 2026 at 11:00 A.M. Eastern Time, because the Company did not have a sufficient number of shares of the Company’s common stock present or represented by proxy at the Annual Meeting to constitute a quorum and to provide stockholders additional time to review the proxy materials and vote on the proposals described in the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 30, 2026 (the “Annual Meeting Proxy Statement”). 

 

A quorum would have been present if shares representing 33 and 1/3% of the common stock outstanding and entitled to vote were present at the Annual Meeting or represented by proxy. At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 32.5% of the outstanding shares of stock entitled to vote, so a quorum did not exist.

 

The Annual Meeting will be reconvened on December 8, 2026 at 11:00 A.M. Eastern Time and will continue to be held in a virtual format. Stockholders will be able to virtually attend the Annual Meeting by visiting https://web.viewproxy.com/AIM/2026.

 

The record date for the determination of stockholders of the Company entitled to vote at the adjourned Annual Meeting remains the close of business on September 28, 2026. No changes have been made to the proposals to be voted on by the stockholders at the Annual Meeting. Stockholders who have previously submitted their proxy or otherwise voted and do not want to change their vote do not need to take any action.

 

About AIM ImmunoTech Inc.

 

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

 

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

 

Cautionary Statement

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements set forth in this press release speak only as of the date hereof. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Such forward-looking statements may include statements relating to the timing of the Annual Meeting and related matters. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company does not undertake to update any forward-looking statements except as required by applicable law.

 

For a discussion of risk factors, please see the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

 

Investor Contact:

 

JTC Team, LLC

Jenene Thomas

908.824.0775

AIM@jtcir.com

 

 

Filing Exhibits & Attachments

5 documents

Keep reading